Welcome to our dedicated page for Golden Arrow Merger Warrant news (Ticker: GAMCW), a resource for investors and traders seeking the latest updates and insights on Golden Arrow Merger Warrant stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Golden Arrow Merger Warrant's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Golden Arrow Merger Warrant's position in the market.
Golden Arrow Merger Corp. (NYSE: GAMCU, GAMC, GAMCW) has canceled its special meeting originally scheduled for December 16, 2022, and withdrawn the proposals set forth in its Definitive Proxy Statement filed with the SEC on November 28, 2022. The company, formed as a blank check entity, aims to pursue mergers or acquisitions, primarily targeting the healthcare sector in developed countries.
On June 4, 2021, Golden Arrow Merger Corp. announced it received a deficiency notice from Nasdaq due to its failure to file the Quarterly Report on Form 10-Q for the period ending March 31, 2021. This delay was a result of the SEC's Staff Statement on accounting considerations for warrants issued by SPACs, impacting many SPACs, including Golden Arrow. The company successfully filed its Form 10-Q by the June 4 deadline and remains compliant with Nasdaq's listing standards. Golden Arrow is focused on acquiring businesses in the healthcare sector.
Golden Arrow Merger Corp. announced the full exercise of the over-allotment option by underwriters in its IPO, resulting in 3,750,000 additional units issued at $10 each. This increases the total units issued to 28,750,000 and total funds raised to $287,500,000 for the trust account. Starting May 7, 2021, IPO unit holders can separately trade Class A common stock and redeemable warrants under the tickers GAMC and GAMCW, respectively, while the units continue trading under GAMCU. The offering was managed by BTIG, LLC and I-Bankers Securities, Inc.
Golden Arrow Merger Corp. has successfully completed its initial public offering (IPO) of 25 million units at $10 each, raising a total of $250 million in gross proceeds. The units, consisting of one share of Class A common stock and one-third of a redeemable warrant, will trade on Nasdaq under the symbol ‘GAMCU’. Following the separation of units, the shares will trade under ‘GAMC’ and the warrants under ‘GAMCW’. The company intends to pursue a merger or acquisition, focusing on the healthcare sector. BTIG, LLC was the sole book-running manager for the offering.
Golden Arrow Merger Corp. announced the pricing of its initial public offering (IPO) of 25 million units at $10.00 each, expected to start trading on Nasdaq under the symbol GAMCU on March 17, 2021. Each unit comprises one share of Class A common stock and one-third of a redeemable warrant, with each whole warrant allowing purchase of a share at $11.50. The offering is set to close on March 19, 2021, and includes a 45-day option for underwriters to purchase additional units. The company is focused on healthcare-related business opportunities.
